Who is eligible for medical weight loss in India?

Key takeaways

• Eligibility is a medical decision based on your whole health, not just a BMI calculator.
• Indian guidelines use lower BMI and waist cut-offs than Western ones because we carry more risky fat at lower weights.
• The large medicine trials enrolled adults with BMI 30 or more, or 27 or more with a weight-related condition.
• Pregnancy, breastfeeding, a personal or family history of medullary thyroid cancer or MEN 2, and certain other conditions rule treatment out or need caution.
• Wanting to lose a few kilos for an event is not, by itself, a medical reason for these medicines.

What do Indian guidelines say?

"Doctor, am I fat enough for the injection?" That is roughly how the question comes. I'm happy to answer it. But the honest answer is never just a number, so let me show you how I actually decide.

In January 2025, an expert group led by Prof. Anoop Misra, with the India Obesity Commission, published a revised definition of obesity for Asian Indians in Diabetes & Metabolic Syndrome: Clinical Research & Reviews. It uses three measures together:

It then divides obesity into two stages:

• Stage 1: BMI above 23 with extra fat but no effect yet on organs or daily activity. Sugar, blood pressure and cholesterol are normal.
• Stage 2: BMI above 23 plus excess abdominal fat, plus either symptoms that limit activity (breathlessness, joint pain) or at least one obesity-related disease such as type 2 diabetes, high blood pressure or fatty liver.

For Stage 1, the paper suggests considering medicines if someone is at risk of progressing (for example, a strong family history of diabetes or heart disease), has gained more than 10% weight despite lifestyle efforts, or has a BMI of 27.5 or more. For Stage 2, it recommends starting medicine early alongside consistent lifestyle measures. The specific drug choices in the paper reflect what was widely available in India at the time it was written; newer GLP-1 options are now prescribed more often, always after assessment.

What BMI do the medicine trials and labels use?

The large trials that established semaglutide and tirzepatide for weight loss (STEP 1 and SURMOUNT-1) enrolled adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition. Prescribing labels internationally describe the target group in similar terms: adults with obesity, or with overweight plus at least one weight-related condition.

For an Indian patient, I read these two frameworks together. That is very important to understand: a BMI of 26 in an Indian with a 95 cm waist, prediabetes and fatty liver may carry more metabolic risk than the number suggests. Equally, a BMI of 28 with a normal waist, sugar and blood pressure may not need medicine at all. My article on why BMI cut-offs are lower for Indians explains the science.

Which conditions strengthen the case for treatment?

Weight-related conditions I look for include:

• prediabetes or type 2 diabetes (see weight loss medicine, prediabetes and diabetes);
• high blood pressure or high cholesterol;
• fatty liver (MASLD);
• PCOS with insulin resistance;
• knee or back pain worsened by weight;
• obstructive sleep apnoea;
• heart disease.

India's burden here is large. The ICMR-INDIAB study estimated that 101 million Indians have diabetes and 136 million have prediabetes, and that about 40% of adults have abdominal obesity.

Who should not take these medicines, or needs extra caution?

The US prescribing information for semaglutide lists as contraindications a personal or family history of medullary thyroid cancer or MEN 2 syndrome, and a previous serious allergy to the medicine. Other situations need careful discussion or rule treatment out for now:

• Pregnancy, trying to conceive or breastfeeding. The NHS advises stopping semaglutide at least two months before trying for a baby.
• Past pancreatitis or gallbladder disease.
• Diabetic eye disease (retinopathy), which needs monitoring.
• Kidney problems, because vomiting or diarrhoea can cause dehydration.
• Diabetes treated with insulin or sulfonylureas, because of low-sugar risk; doses may need adjustment.
• Upcoming surgery under anaesthesia, because slower stomach emptying matters for safety; tell your surgeon and anaesthetist.
• Mood problems. The label lists monitoring for depression or suicidal thoughts.

A history of eating difficulties also deserves an open, unhurried conversation before any appetite-reducing medicine.

And to be straightforward about it: wanting to fit into a lehenga for your cousin's wedding next month is understandable, but it is not a medical reason for these medicines.

What does an eligibility assessment involve?

A proper assessment should cover:

1. Measurements: weight, height, BMI, waist, and ideally waist-to-height ratio.
2. History: past weight attempts, family history, medicines, periods and pregnancy plans for women, sleep, alcohol, work hours.
3. Health conditions and red flags from the list above.
4. Baseline tests as needed: typically blood sugar or HbA1c, lipids, liver and kidney function, thyroid, and sometimes vitamin levels.
5. Your goals and preferences, including whether you are open to strength training and protein changes, and how you feel about the long-term plan.

If you are not eligible, a good doctor will tell you so and suggest what would help instead. If you are, you should receive a written plan before paying for medicine.

How I approach this at Dr Tvacha

The Endgame Weight Programme begins with a Rs 499 eligibility consult by video, available anywhere in India. I review your measurements, history and reports, and tell you plainly whether medicine is appropriate. If it is, you get the fees in writing (Rs 30,000 a month or Rs 1,00,000 for four months, medicine included), with monthly reviews and a taper plan from month one. The choice to go ahead is entirely yours.

Written by

Dr Amit KarkhanisAesthetic Physician · MBBS, Dip. Dermatology (UK) · Reg. No. 2001/02/1124

Founder of Dr Tvacha, practising in Thane since 2005. Leads the weight loss and hair programmes.